Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Linda A Feagins, Dallas VA Medical Center
ClinicalTrials.gov Identifier:
NCT01647568
First received: July 19, 2012
Last updated: NA
Last verified: July 2012
History: No changes posted
  Purpose

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.

Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.


Condition
Post-polypectomy Bleeding
Anti-platelet Therapy
Colonoscopy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Dallas VA Medical Center:

Enrollment: 715
Study Start Date: December 2009
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Control
Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
Thienopyridine Users
Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients presenting to the GI lab for elective colonoscopy.

Criteria

Inclusion Criteria:

  • Patients presenting to the GI lab for elective colonoscopy

Exclusion Criteria:

  • Patients on Coumadin or other anti-coagulants
  • Patients with Inflammatory Bowel Disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01647568

Locations
United States, Texas
Dallas VA Medical Center
Dallas, Texas, United States, 75216
Sponsors and Collaborators
Dallas VA Medical Center
  More Information

No publications provided by Dallas VA Medical Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Linda A Feagins, Staff Gastroenterologist, Dallas VA Medical Center
ClinicalTrials.gov Identifier: NCT01647568     History of Changes
Other Study ID Numbers: DVAMC-09-084
Study First Received: July 19, 2012
Last Updated: July 19, 2012
Health Authority: United States: Federal Government

ClinicalTrials.gov processed this record on September 30, 2014